Five oncology therapies win approval for PBS listing

Medications for breast, prostate, colorectal and urothelial cancer have won positive recommendations for PBS listing from the Pharmaceutical Benefits Advisory Committee (PBAC). At its March 2021 meeting the PBAC made the following positive recommendations: Abemaciclib  for breast cancer. The PBAC recommended the listing of abemaciclib (Verzenio)in combination with fulvestrant, for the treatment of non-premenopausal patients ...

Already a member?

Login to keep reading.

© 2022 the limbic